Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314393 | 1.00 | MAOB (0.39) | MAOBDRD2DRD3KMT2AALDH1A1 | |
| SCHEMBL14134841 | 0.95 | MAOB (0.38) | MAOBDRD2DRD3KMT2AALDH1A1 | |
| SCHEMBL12432842 | 0.95 | MAOB (0.38) | MAOBDRD2DRD3KMT2AALDH1A1 | |
| SCHEMBL2316735 | 0.95 | MAOB (0.38) | MAOBDRD2DRD3KMT2AALDH1A1 | |
| SCHEMBL12433996 | 0.95 | DRD2 (0.35) | MAOBDRD2DRD3KMT2ACXCR3 | |
| SCHEMBL2317089 | 0.94 | HTR7 (0.35) | MAOBDRD2DRD3KMT2AALDH1A1 | |
| SCHEMBL14135130 | 0.94 | HTR7 (0.35) | MAOBDRD2DRD3KMT2AALDH1A1 | |
| SCHEMBL12433995 | 0.94 | HTR7 (0.35) | MAOBDRD2DRD3KMT2AALDH1A1 | |
| SCHEMBL12432614 | 0.94 | DRD2 (0.34) | MAOBDRD2DRD3KMT2ALTA4H | |
| SCHEMBL2315661 | 0.94 | DRD2 (0.34) | MAOBDRD2DRD3KMT2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| EP-2125782-B1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | disclosed |
| WO-2008101905-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | CYP2D6, CYP2B6, CYP2C9 | MAOB 542/4885DRD2 1941/4885DRD3 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.